Managing Residual Cardiovascular Risk with Fenofibrate
Although statins are the first-line treatment for hyperlipidaemia, risk of cardiovascular disease remains even with treatment. Fibrates such as fenofibrate have been shown to have a role in further reducing cardiovascular risk, especially in cases of metabolic syndrome and severe hyperlipidaemia and dyslipidaemia.
Modern Medicine – Issue 2 2021
